BLA Submitted for IB1001 for Hemophilia B

Inspiration Biopharmaceuticals announced that it has submitted a Biologics License Application (BLA) to the FDA for the approval of IB1001 for the treatment and prevention of bleeding in individuals with hemophilia B. 

The IB1001 BLA filing includes a comprehensive set of pharmacokinetics safety, and efficacy data from a Phase 3 clinical trial in people affected by hemophilia B.  A surgery substudy was also included.

IB1001 is an intravenous recombinant factor IX product.

For more information visit